You won't get it automatically when you export electricity you're not using. You'll need to sign up with an energy company, and your solar PV system must have been installed by a registered MCS (Microgeneration Certification Scheme) installer. REZOLSTA must not be combined with medicinal products that are highly dependent on CYP3A for clearance and for which increased systemic exposure is associated with serious and/or life threatening events (narrow therapeutic index). Based on theoretical considerations, REZOLSTA is expected to increase the exposure of lomitapide when co-administered. There are no data regarding the use of darunavir or cobicistat in patients with severe hepatic impairment. Severe hepatic impairment could result in an increase of darunavir and/or cobicistat exposure and a worsening of its safety profile. Therefore, REZOLSTA must not be used in patients with severe hepatic impairment (Child-Pugh Class C) (see sections 4.3, 4.4 and 5.2).

If a patient vomits within 4 hours of taking the medicine, another dose of REZOLSTA should be taken with food as soon as possible. If a patient vomits more than 4 hours after taking the medicine, the patient does not need to take another dose of REZOLSTA until the next regularly scheduled time. Based on theoretical considerations REZOLSTA is expected to increase these antiarrhythmic plasma concentrations. As REZOLSTA contains darunavir and cobicistat, interactions that have been identified with darunavir (in combination with cobicistat or with low dose ritonavir) or with cobicistat determine the interactions that may occur with REZOLSTA. Interaction trials with darunavir/cobicistat, darunavir/ritonavir and with cobicistat have only been performed in adults. Life-threatening and fatal drug interactions have been reported in patients treated with colchicine and strong inhibitors of CYP3A and P-glycoprotein (see section 4.5). Palpitations were reported in 0.7% of the placebo patients, 0.9% of the 1 mg prucalopride patients, 0.9% of the 2 mg prucalopride patients and 1.9% of the 4 mg prucalopride patients. The majority of patients continued using prucalopride. As with any new symptom, patients should discuss the new onset of palpitations with their physician.The efficacy and safety of Resolor in paediatric patients (aged 6 months to 18 years) with functional constipation, were evaluated in an 8-week double-blind, placebo-controlled trial (N=213), followed by a 16 week open-label comparator-controlled (Polyethylene glycol 4000) study of up to 24 weeks (N=197). The starting dose administered was 0.04 mg/kg/day titrated between 0.02 and 0.06 mg/kg/day (to a maximum of 2 mg daily) for children weighing ≤50 kg given as an oral solution of Resolor or matching placebo. Children weighing >50 kg received 2 mg/day Resolor tablets or matching placebo. Number of subjects with virologic failure and phenotype data that show a loss of susceptibility to PIs at endpoint compared to baseline d, n/N These seizures are brief and not dangerous. However, you should have your child examined by a doctor if one happens.

Clinical monitoring and dose reduction is required when a DOAC transported by P gp but not metabolised by CYP3A4, including dabigatran etexilate and edoxaban, is co administered with REZOLSTA.Efficacy of darunavir/cobicistat fixed-dose combination 800/150 mg once daily in ART-naïve patients Developed by the nation’s leading solar energy organizations, the Smart Electric Power Alliance (SEPA) and the Solar Energy Industries Association (SEIA), RE+ reflects an ongoing entrepreneurial approach to renewing best practices across the clean energy landscape as the marketplace evolves. This recommendation is different from ritonavir-boosted darunavir. Consult the Summary of Product Characteristics for darunavir for further details. Prices vary during the year. For example, between May 2020 and April 2021, prices per kW were highest in April, May and February and lowest between August and October, according to BEIS. As REZOLSTA contains darunavir and cobicistat, the adverse reactions associated with each of the individual compounds may be expected.

Therapy should be initiated by a healthcare provider experienced in the management of HIV infection. In case of severe diarrhoea, the efficacy of oral contraceptives may be reduced and the use of an additional contraceptive method is recommended to prevent possible failure of oral contraception (see the prescribing information of the oral contraceptive). Co-administration of REZOLSTA and other medicinal products that inhibit CYP3A may decrease the clearance of darunavir and cobicistat and may result in increased plasma concentrations of darunavir and cobicistat (e.g. azole antifungals such as clotrimazole). These interactions are described in the interaction table below. The efficacy and safety of Resolor in patients (aged ≥18 or older) with chronic constipation, were evaluated in a 24 week multicentre, randomised, double-blind, placebo controlled study (N=361). The proportion of patients with an average weekly frequency of ≥3 Spontaneous Complete Bowel Movements (SCBMs) per week (i.e., responders) over the 24-week double-blind treatment phase was not statistically different (p=0.367) between the Resolor (25.1%) and placebo (20.7%) treatment groups. The difference between treatment groups in the average weekly frequency of ≥3 SCBMs per week was not statistically significant over Weeks 1-12 which is inconsistent with the 5 other multicentre, randomised, double-blind, 12-week placebo controlled studies demonstrating efficacy at this timepoint in adult patients. The study is therefore considered to be inconclusive with respect to efficacy. However, the totality of the data including the other double-blind placebo controlled 12 week studies support the efficacy of Resolor. The safety profile of prucalopride in this 24 week study was consistent with that seen in the previous 12 week studies.Darunavir is an inhibitor of the dimerisation and of the catalytic activity of the HIV-1 protease (K D of 4.5 x 10 -12M). It selectively inhibits the cleavage of HIV encoded Gag-Pol polyproteins in virus infected cells, thereby preventing the formation of mature infectious virus particles.